Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Debt to Equity (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Debt to Equity data on record, last reported at $1.37 in Q4 2025.

  • For Q4 2025, Debt to Equity rose 51.01% year-over-year to $1.37; the TTM value through Dec 2025 reached $1.37, up 51.01%, while the annual FY2025 figure was $1.37, 51.01% up from the prior year.
  • Debt to Equity reached $1.37 in Q4 2025 per MRVI's latest filing, up from $1.19 in the prior quarter.
  • Across five years, Debt to Equity topped out at $2.5 in Q1 2021 and bottomed at $0.56 in Q1 2025.
  • Average Debt to Equity over 5 years is $0.98, with a median of $0.83 recorded in 2022.
  • Peak YoY movement for Debt to Equity: tumbled 67.54% in 2022, then skyrocketed 51.01% in 2025.
  • A 5-year view of Debt to Equity shows it stood at $1.37 in 2021, then tumbled by 57.54% to $0.58 in 2022, then rose by 13.89% to $0.66 in 2023, then surged by 37.1% to $0.91 in 2024, then surged by 51.01% to $1.37 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $1.37 in Q4 2025, $1.19 in Q3 2025, and $0.62 in Q2 2025.